Pfizer’s C. difficile vaccine, positive Phase II data

Pfizer announced that the Phase II study designed to assess the Clostridium difficile vaccine candidate, PF-06425090, has provided positive data, based on a pre-planned interim analysis. The randomized trial examined the safety, tolerability, and immunogenicity of the vaccine in healthy adults aged between 65 and 85. Based on these positive findings, the product will now progress into Phase III. PF-06425090 was granted Fast Track designation by FDA in August 2014. (Source Business Wire)